Emcure Pharmaceuticals Limited
Incorporated in 1981, Emcure Pharmaceuticals Limited is an Indian company that develops, manufactures, and markets a wide range of pharmaceutical products globally across several major therapeutic areas.
What Emcure files
- Others61
- Investor Meet33
- Updates23
- Important22
- Board Meeting10
- JV/Acquisition9
Emcure Pharmaceuticals delivered a strong Q1FY27. Revenue surged 22.8% YoY to ₹2,580.4 Cr, while Net Profit jumped 36.2% YoY to ₹292.5 Cr. The International business was a key driver, growing 34.2% YoY and contributing 58% of total revenue with robust performance across Europe, RoW, and Canada. Domestic business also saw...
**1. Business Performance:** Emcure posted robust FY26 results: revenue hit ₹9,204 Cr (+16.6% YoY). Profitability surged, with EBITDA margin at 19.4% and Adjusted PAT margin at 10.9%. Growth was balanced, driven by domestic and international markets, especially complex product sales. **2. Growth Drivers or Strategy:** Growth drivers include a strong...
Here is a concise, retail-friendly summary: **Business Performance:** Emcure Pharma had a stellar FY26, crossing US$1 billion in revenue with 16.6% growth, beating guidance. Adjusted PAT surged over 40%, and base business EBITDA margins expanded 100 bps. International markets fueled a robust 22% YoY growth, while domestic business saw resilient...
Emcure Pharma delivered strong performance, achieving mid-high teens revenue growth over the last seven quarters, including 16.5% in 9M FY26 and over 18% in FY25. This growth was fueled by a robust domestic market across key therapies and strong international performance driven by new launches. The company also saw significant...
Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation